Improving Sexual Health In Men With Prostate Cancer: Randomised Controlled Trial Of Exercise And Psychosexual Therapies
Funder
National Health and Medical Research Council
Funding Amount
$583,416.00
Summary
Sexual dysfunction is one of the most common and distressing side effects of prostate cancer. Despite being a critical survivorship care issue, there is a clear gap in knowledge surrounding the optimal treatment of sexual dysfunction in men with prostate cancer. This project examines whether exercise aids in the management of sexual dysfunction and explores if an integrated treatment model incorporating pharmacological, exercise and psychosexual therapies maximises improvement in sexual health.
Can Exercise Delay Transition To Active Therapy In Men With Low Grade Prostate Cancer? A Multi-Centre Randomized Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$604,429.00
Summary
Prostate cancer overdiagnosis is associated with increased rates of overtreatment and associated morbidity. Although nearly half of Australian men diagnosed with low risk prostate cancer are managed with active surveillance there are no established recommendations for slowing disease progression and delaying transition to active treatment. The proposed study would be the first to determine the efficacy of a comprehensive exercise program during active surveillance for prostate cancer.
Melanoma Mutation Profiling For Personalised Treatment
Funder
National Health and Medical Research Council
Funding Amount
$571,191.00
Summary
Melanoma is an aggressive skin cancer, and the leading cause of skin cancer related deaths. Disease spread is difficult to detect and extremely difficult to cure. This bleak clinical outcome is changing with the development of personalised therapies which include small molecule inhibitors to treat metastatic melanoma. Here we seek to identify the spectrum of mutations in patient tumours and circulating tumour cells for advanced personalised treatment.
A Phase III Trial Comparing Adjuvant Versus Salvage Radiotherapy For High Risk Patients Post Radical Prostatectomy
Funder
National Health and Medical Research Council
Funding Amount
$819,138.00
Summary
About half of all patients Treated with an operation to remove their prostate cancer have a high chance of the cancer coming back. Giving immediate radiotherapy to all patients will improve cure rates but does not benefit all men and can cause significant side effects. This study explores whether it is safe to wait and only give radiotherapy when there is a rising PSA after surgery indicating active cancer. A total of 470 men from Australasia will enter this study comparing the two approaches.
The Impact Of Therapy On T-cell Recognition Of Mutated Tumour Neo-antigens
Funder
National Health and Medical Research Council
Funding Amount
$1,126,685.00
Summary
Cancer is caused by mutations which should be 'seen' and destroyed by the patients immune cells, similar to how immune cells protect us against viruses. But they don't. This grant will study how current cancer treatments help the immune cells 'see' these mutations. We will undertake these studies in the important cancers lung cancer and mesothelioma.
Understanding And Applying Macrophage-mediated Effects On Liver Progenitor Cells To Treat Liver Disease.
Funder
National Health and Medical Research Council
Funding Amount
$628,109.00
Summary
As liver cancer risk correlates with increased liver stem/progenitor cell numbers, therapies that reduce their numbers will reduce cancer development. On the contrary, therapies to increase progenitor cell numbers will assist their use in cell therapy-based approaches or artificial liver devices to treat chronic liver disease. This project will determine how to use inflammatory cells to manipulate progenitor cell numbers.
Compartmental Analysis Of T-cell Responses In Thoracic Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$851,403.00
Summary
To improve immune therapy for cancer we have to be able to determine how cancer patients ‘see’ mutated cancer proteins. Blood is the easiest & most useful source of immune ‘killer’ cells for that task, but the lymph node that drains the tumour and the fluid that bathes a tumour probably contain a much higher number of these killer cells than blood. If so, studying them would help us better track responses to therapy and enable us to choose the best mutated proteins for a vaccine.
The Relationship Between Cancer Surgery, Lymph Nodes, T Cells And Immunotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$960,585.00
Summary
Cancer treatment involves surgery for millions of patients annually, however, many patients do relapse. Surgery often involves removal of cancer-associated lymph nodes at the site. To improve surgical outcomes new immunotherapy strategies aim to activate the patients’ immune cells to eradicate tumours. However the main repository for these immune cells is in the very lymph tissue removed at surgery. This project will investigate the role of remaining lymph nodes in patient recovery/response.
Exposure To Diesel Exhaust And Lung Cancer Risk In Australia
Funder
National Health and Medical Research Council
Funding Amount
$581,519.00
Summary
Exposure to diesel exhaust increases the risk of lung cancer. One in five Australians is exposed to diesel exhaust in the workplace. This project will provide an exposure-response relation between diesel exhaust and lung cancer based on Australia-specific data. We will also estimate the number of lung cancer cases due to diesel exhaust exposure in Australia. We will do this by studying all miners in WA in the last 15 years, by linking several databases that are available in WA.
Temporal Trends In The Incidence, Site And Survival Of Metastatic Breast Cancer In Australia
Funder
National Health and Medical Research Council
Funding Amount
$190,494.00
Summary
There have been major advances in breast cancer treatment over the last decade. This project will use information collected from the NSW cancer registry and hospitals to report on changes in the type and risk of breast cancer spread and survival for women with a new diagnosis of breast cancer before and after new treatments introduced since 2005. This information is essential for doctors to provide women with up-to-date information; and for planning appropriate health services and research.